Barostim therapy targets an annual total addressable market of $2.2 billion. The therapy has demonstrated an 85% reduction in hospitalizations among heart failure patients. CVRx revised its ...

CVRx Inc (NASDAQ:CVRX) reported a strong Q3 with double-digit year-over-year revenue growth and an expanded commercial footprint. The company successfully onboarded new sales reps, contributing to ...

CVRx Inc. (CVRX) reported its third-quarter 2025 earnings, showing a slight beat on both earnings per share (EPS) and revenue forecasts. Despite this, the company’s stock experienced a decline in ...

Earnings call CVRx reported Q3 2025 revenue of $14.7M, up 10% YoY, with gross margin expanding to 87% from 83%. Management narrowed FY25 guidance and expects mid-teens revenue growth in 2026, ...

MINNEAPOLIS, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative ...